Author: Lisa Ostrin, OD, PhD, FAAO, FARVO
Over the past few decades, myopia research has transformed. What was once largely focused on prevalence and risk factors has evolved into a field driven by clinical trials, technological innovation, and increasingly sophisticated experimental approaches. Clinicians have tools to manage myopia, and industry continues to deliver new solutions. As the 20th International Myopia Conference (IMC 2027) approaches, we have an opportunity to reflect on how far the field has come and shape where it is headed.
Some of the most important questions are still ahead of us:
- Novel treatments slow myopia, but what are their mechanisms?
- How do changes in retinal signaling translate into changes in eye growth?
- What is the role of the choroid?
- How do light exposure, visual behavior, and diurnal biology interact?
- How can these factors be integrated to support individualized care for patients?
Answering these questions requires a shift in focus from identifying what works to understanding how and why it works. This shift will require connecting ideas across basic science, clinical research, and emerging technologies.
IMC 2027 is uniquely positioned to support this transition. The meeting brings together a global community of researchers, clinicians, and industry partners to exchange ideas, challenge assumptions, and define what comes next. From wearable sensors that capture real-world visual environments, to advances in imaging and data science, to new insights into how the visual system regulates eye growth. The field is moving fast, and IMC is where those conversations happen. As myopia continues to grow as a public health concern, collaboration across disciplines and regions is essential.
This time, we will gather in Houston, a city known for solving complex problems and pushing boundaries. Join us in March 2027 as we take on the challenge, “Houston, we have a myopia problem!” Bring your questions, your ideas, and your curiosity.